Eisai sues FDA over shortened marketing period for 2 drugs

Eisai filed a lawsuit to force the FDA to extend the drugmaker's marketing exclusivity period on diet drug Belviq and epilepsy drug Fycompa after listing delays by the U.S. Drug Enforcement Agency delayed the drugs' launch, thus shortening the marketing exclusivity period.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Dallas, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Teaching Associate (Hospitality Management)
University of Illinois at Urbana-Champaign
Urbana, IL
Director, Global Regulatory Affairs
Rodan and Fields, LLC
San Francisco, CA
Senior Compliance Analyst
ACell, Inc.
Columbia, MD